Ninet Sinaii

Ninet Sinaii

Auto-generated profile, based on publicly available information

Ninet Sinaii

Biostatistics and Clinical Epidemiology Service, National Institutes of Health Clinical Center, National Institute of Health , Bethesda, MD 20892

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2022 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SSSarah Shnayder
Sarah Shnayder
RARezvan Ameli
Rezvan Ameli
NSNinet Sinaii
Ninet Sinaii
ABAnn Berger
Ann Berger
MAManish Agrawal
Manish Agrawal

29 April 2020 in Journal of Adolescent Health
Verified
Journal Article
Closed access
RPRebecca W. Persky
Rebecca W. Persky
SGSiobhan M. Gruschow
Siobhan M. Gruschow
NSNinet Sinaii
Ninet Sinaii
CCClaire Carlson
Claire Carlson
JGJill P. Ginsberg
Jill P. Ginsberg
NDNadia L. Dowshen
Nadia L. Dowshen

8 January 2021 in European journal of pain
Verified
Journal Article
Closed access
PDF file
VPVy T. Phan
Vy T. Phan
PSPamela Stratton
Pamela Stratton
HTHannah K. Tandon
Hannah K. Tandon
NSNinet Sinaii
Ninet Sinaii
JAJacqueline V. Aredo
Jacqueline V. Aredo
JSJay P. Shah
Jay P. Shah

2 March 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ATAhmed Torky
Ahmed Torky
NSNinet Sinaii
Ninet Sinaii
SJSmita Jha
Smita Jha
JDJay Desai
Jay Desai
DEDiala El-Maouche
Diala El-Maouche
DMDeborah P Merke
Deborah P Merke
Context Patients with congenital adrenal hyperplasia (CAH) are exposed to hyperandrogenism and supraphysiologic glucocorticoids, both of which can increase risk of metabolic morbidity. Objective Our aim was to evaluate cardiovascular and metabolic morbidity risk in a longitudinal study of patients with CAH spanning both childhood and adulthood. Design and Setting Patients with classic CAH followed for a minimum of 5 years during both childhood and adulthood (n = 57) at the National Institutes of Health were included and compared with the US general population using NHANES data. Main outcome measures Obesity, hypertension, insulin resistance, fasting hyperglycemia, and dyslipidemia. Results Compared to the US population, patients with CAH had higher (P < 0.001) prevalence of obesity, hypertension, insulin resistance, fasting hyperglycemia, and low high-density lipoprotein (HDL) during childhood and obesity (P = 0.024), hypertension (P<0.001), and insulin resistance (P < 0.001) during adulthood. In our cohort, obesity, hypertension, fasting hyperglycemia, and hypertriglyceridemia began prior to age 10. During childhood, increased mineralocorticoid dose was associated with hypertension (P = 0.0015) and low HDL (P = 0.0021). During adulthood, suppressed androstenedione was associated with hypertension (P = 0.002), and high low-density lipoprotein (P = 0.0039) whereas suppressed testosterone (P = 0.003) was associated with insulin resistance. Elevated 17-hydroxyprogesterone, possibly reflecting poor disease control, was protective against high cholesterol (P = 0.0049) in children. Children whose mothers were obese (maternal obesity) had increased risk of obesity during adulthood (P = 0.0021). Obesity, in turn, contributed to the development of hypertension, insulin resistance, and hypertriglyceridemia in adulthood. Conclusion Patients with CAH develop metabolic morbidity at a young age associated with treatment-related and familial factors. Judicious use of glucocorticoid and mineralocorticoid is warranted.

16 April 2024 in Genes
Verified
Journal Article
Open access
PDF file
PSPashtun Shahim
Pashtun Shahim
GNGina Norato
Gina Norato
NSNinet Sinaii
Ninet Sinaii
HZHenrik Zetterberg
Henrik Zetterberg
KBKaj Blennow
Kaj Blennow
CGChristopher Grunseich
Christopher Grunseich
Background: Neurofilament proteins have been implicated to be altered in amyotrophic lateral sclerosis (ALS). The objectives of this study were to assess the diagnostic and prognostic utility of neurofilaments in ALS. Methods: Studies were conducted in electronic databases (PubMed/MEDLINE, Embase, Web of Science, and Cochrane CENTRAL) from inception to 17 August 2023, and investigated neurofilament light (NfL) or phosphorylated neurofilament heavy chain (pNfH) in ALS. The study design, enrolment criteria, neurofilament concentrations, test accuracy, relationship between neurofilaments in cerebrospinal fluid (CSF) and blood, and clinical outcome were recorded. The protocol was registered with PROSPERO, CRD42022376939. Results: Sixty studies with 8801 participants were included. Both NfL and pNfH measured in CSF showed high sensitivity and specificity in distinguishing ALS from disease mimics. Both NfL and pNfH measured in CSF correlated with their corresponding levels in blood (plasma or serum); however, there were stronger correlations between CSF NfL and blood NfL. NfL measured in blood exhibited high sensitivity and specificity in distinguishing ALS from controls. Both higher levels of NfL and pNfH either measured in blood or CSF were correlated with more severe symptoms as assessed by the ALS Functional Rating Scale Revised score and with a faster disease progression rate; however, only blood NfL levels were associated with shorter survival. Discussion: Both NfL and pNfH measured in CSF or blood show high diagnostic utility and association with ALS functional scores and disease progression, while CSF NfL correlates strongly with blood (either plasma or serum) and is also associated with survival, supporting its use in clinical diagnostics and prognosis. Future work must be conducted in a prospective manner with standardized bio-specimen collection methods and analytical platforms, further improvement in immunoassays for quantification of pNfH in blood, and the identification of cut-offs across the ALS spectrum and controls.

12 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RARezvan Ameli
Rezvan Ameli
NSNinet Sinaii
Ninet Sinaii
MLMaría José Luna
María José Luna
JCJulia Cheringal
Julia Cheringal
BGBrunilde Gril
Brunilde Gril
ABAnn Berger
Ann Berger
Two hundred patients with severe and/or life-threatening disease were recruited form the NIH Clinical Center and participated in the validation of the NIH-HEALS, which included exploratory factor analysis, principal component analysis, reliability, convergent validity, and divergent validity analyses. Item-reducing principal components analysis and internal consistency and split-half reliability demonstrated excellent internal consistency and split-half reliability (Cronbach’s alpha = 0.89, split-half reliability = 0.95). Exploratory factor analysis revealed a three-factor structure, namely Connection (including religious, spiritual, and interpersonal), Reflection & Introspection, and Trust & Acceptance. Seven items were not retained. Convergent and divergent validity of 35-item NIH-HEALS against other validated measures of healing and spirituality provided strong evidence for its validity. As predicted, the Healed factor of the Self-Integration Scale (SIS), and Meaning, Peace, and Faith factors of the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being-12 Scale (FACIT-SP12) were all positively and significantly correlated with the NIH-HEALS and its three factors. Divergent validity was also confirmed by the significant negative correlation between the NIH-HEALS and the Codependent factor on the SIS. Confirmatory Factor Analyses revealed good model fit by GFI (0.96), adjusted GFI (0.95), SRMR (0.077), and RMSEA (0.065), supporting the use of the NIH-HEALS with 35 items.